Digital health helping cancer diagnosis - Pharmaphorum

The FDA has been championing digital health of late with wide-ranging guidance that derives from the 21st Century Cures Act. This legislation acknowledges the potential that digital health has to make a difference in patient care, potentially leading to more precise therapies. Several developments this week show that the regulator is right to be excited about its potential. Some of the most exciting advances have come in the field of cancer – medical devices firm Angle has produced a new analysis showing that its liquid biopsy device Parsortix could be used instead of conventional tissue biopsies. Parsortix works by monitoring a patient's bloodstream for circulating cancer cells and the University of Southern California research adds to the body of evidence showing that liquid biopsies could replace invasive and unpleasant tissue biopsies in the future.